Growth Metrics

Boston Scientific (BSX) Non-Current Deferred Tax Liability (2016 - 2025)

Boston Scientific (BSX) has disclosed Non-Current Deferred Tax Liability for 17 consecutive years, with $220.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 41.94% to $220.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $220.0 million through Dec 2025, up 41.94% year-over-year, with the annual reading at $220.0 million for FY2025, 41.94% up from the prior year.
  • Non-Current Deferred Tax Liability hit $220.0 million in Q4 2025 for Boston Scientific, down from $242.0 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $336.0 million in Q1 2021 to a low of $79.0 million in Q4 2021.
  • Historically, Non-Current Deferred Tax Liability has averaged $186.2 million across 5 years, with a median of $156.5 million in 2024.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: crashed 76.06% in 2021 and later soared 130.43% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $79.0 million in 2021, then soared by 82.28% to $144.0 million in 2022, then decreased by 6.94% to $134.0 million in 2023, then increased by 15.67% to $155.0 million in 2024, then skyrocketed by 41.94% to $220.0 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for BSX at $220.0 million in Q4 2025, $242.0 million in Q3 2025, and $226.0 million in Q2 2025.